FK-506-Alkaline Phosphatase

Catalog Number: FK5


Precursor FK-506 (Tacrolimus)
  
Concentration 100 Units/ml (2000 Units/mg)
  
Form Liquid in 7 mM PBS, pH 7.7 with 0.05% Sodium Azide
  
Storage 4° C
  
Addition Remarks Use for EIA. Displaying high binding with Anti-FK-506 antibody for assay development with sensitivity of ~1 ng/ml





Enzyme Immunoassay for the Determination of FK-506 in Sample Extract

Introduction

FK-506 (Tacrolimus) is a microlide lactone of fugal origin with potent immunosuppressive properties. FK-506 is used for primary or rescue immunosuppressant in patients after solid organ transplantation. Clinically relevant FK-506 side effects are nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension. Most of these side effects are more closely related to FK-506 blood levels than dosage, therefore therapeutic drug monitoring of FK-506 levels is a prerequisite for therapy.

Principle of FK-506 Determination

The enzyme immunoassay for FK-506 is based on the competition between the FK-506 to be assayed and the FK-506-Alkaline Phosphatase conjugate, for binding to rabbit antibody directed against FK-506, coated onto microwells. The sample containing the FK-506, and the FK-506-Alkaline Phosphatase conjugate, when added to the microtiter wells, compete for binding to a limiting number of antibody sites. After incubation, each well is rinsed in order to remove non-bound components. The bound enzymatic activity is then measured by the addition of a chromogenic substrate. The intensity of the color developed is inversely proportional to the concentration of FK-506 in the sample. The concentration is calculated on the basis of a standard curve.

Reagents

Assay Procedure

Cross Reactivity

Cross react with Ascomycin. Do not cross react with Gentamicin, Neomycin, Tylosin, Sulfamethazine, Sulfadimethoxine, Zearalenone and Narasin.

FK-506 Inhibition Curve